Actions
Pages
Subscribe for newsletter
Stories
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
Story
Terran Orbital’s $15 million contract for hardware and integration services to support U.S. Space Force experiments enhance the capabilities of national security satellites and defense capabilities.
This partnership exemplifies how emergent technologies can bolster the U.S. defense infrastructure, ensuring a competitive edge in space. It underscores the vital role of innovation in national security and the increasing reliance on small satellites for versatile, cost-effective solutions in space exploration and defense.
The contract was facilitated by Axient Corp, acting on behalf of the Air Force Research Laboratory (AFRL), to manage small-satellite military experiments following their own contract win in September 2023.
This announcement comes on the heels of Lockheed Martin’s proposal to acquire Terran Orbital a few days earlier. Lockheed Martin already owns a significant stake - over $500 million - in the company.
"Terran Orbital's partnership with the U.S. Space Force signifies a pivotal moment in our quest for superior space capabilities, ensuring our readiness and strategic advantage in an increasingly contested domain," remarked Marc Bell, CEO of Terran Orbital.
Delivery of the Ambassador platforms is expected within 12 months, aligning with the technologies used for the Space Development Agency’s Tranche 1 Transport Layer satellites. The successful deployment and operation of these satellites could lead to further contracts and solidify Terran Orbital's position as a key player in defense and commercial space missions.
Story
Frontier Lithium and Mitsubishi have formed a joint venture for the PAK Lithium Project in Ontario. This partnership aims to develop the region's first fully integrated lithium mining and processing operation, with Mitsubishi initially acquiring a 7.5% interest for C$25 million, alongside options for further investment.
The investment from Mitsubishi will be used to initiate Ontario’s first fully integrated lithium mining and processing operation. Both companies will seek additional financing to bring the PAK project into production.
The collaboration underscores the PAK Lithium Project's critical role in strengthening the North American EV battery materials supply chain. It aligns with broader efforts, such as the Canada-Japan memorandum of cooperation, to ensure a sustainable and reliable global battery supply chain, highlighting the project's strategic importance.
Mitsubishi's involvement is seen as a vote of confidence in Frontier Lithium's operational capabilities and the PAK project's potential. This partnership is expected to de-risk Frontier Lithium stock for retail investors, illustrating the project's strategic importance in supplying lithium to North American EV battery manufacturers.
The PAK project, first drilled in 2013, is recognized for its high-grade lithium deposits, boasting a US$1.74 billion net present value. It holds the title for the highest-grade mineral resource in North America, with significant lithium oxide (Li2O) concentrations in its measured, indicated, and inferred reserves.
Trevor Walker, CEO of Frontier Lithium, stated, "This partnership with Mitsubishi is a significant milestone for Frontier Lithium and a vote of confidence in our vision to become a key lithium supplier to the North American EV battery materials supply chain."
The definitive feasibility study (DFS) completion in 2025 will be a critical next step, determining the project's full scale and investment requirements for production commencement.
This partnership is pivotal for the global lithium market and the North American EV industry, meeting the increasing demand for battery materials. It promises long-term value creation and economic benefits for various stakeholders, including shareholders, communities, and governments, emphasizing sustainable mineral resource development.
Story
Innovators
Scroll
Open
Close